var data={"title":"Natalizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Natalizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6631?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=natalizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Natalizumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709166\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Progressive multifocal leukoencephalopathy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti&ndash;JC virus (JCV) antibodies. These factors should be considered in the context of expected benefit when initiating and continuing treatment with natalizumab.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients on natalizumab for any new sign or symptom that may be suggestive of PML. Withhold natalizumab dosing immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of PML, natalizumab is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the TOUCH prescribing program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200027\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tysabri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5594359\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tysabri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200046\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gastrointestinal Agent, Miscellaneous;</li>\n      <li>\n        Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200029\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis:</b> IV: 300 mg infused over 1 hour every 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease: </b> IV: 300 mg infused over 1 hour every 4 weeks; discontinue if therapeutic benefit is not observed within initial 12 weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant use with corticosteroids:</i> For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant use with immunosuppressants (eg, azathioprine, cyclosporine, 6-mercaptopurine, or methotrexate) or inhibitors of TNF-alpha:</i> Avoid concomitant use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200030\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200031\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200032\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200011\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tysabri: 300 mg/15 mL (15 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199999\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234120\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      Canada: Natalizumab is only available through a controlled distribution program called Biogen ONE Support Program (855-676-6300 or http://www.BIOGENcareforMS.ca). This program is associated with the prescribing, administration, and monitoring of Canadian patients receiving natalizumab. Clinicians are educated on the appropriate use of natalizumab and are expected to discuss the benefits/risks of therapy. Clinicians should evaluate patients every 6 months during treatment. Under this program, only prescribers and pharmacies registered with the program are able to prescribe and dispense natalizumab. In addition, natalizumab can only be dispensed to patients who are registered and meet all the conditions of the Biogen ONE Support Program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7885623\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/1215104s959lbl.pdf#page=30&amp;token=imYmIeMRaA/PHRwRwZKlfpDKOPTWQvBUZj0nrrfeRLFTt/dH78wfpLAxbTpoui/cyMQZ6mMgMIxXl063yxVS9ajxzjvlmAbiZh7RkrRqcjGRwC+CkfRa9NrQWWX7As9O&amp;TOPIC_ID=10252\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/1215104s959lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200013\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">If stored under refrigeration, allow solution to warm to room temperature prior to administration. Diluted solution should be infused over 1 hour; do not administer by IV bolus or push. Patients should be closely monitored for signs and symptoms of hypersensitivity during the infusion and for at least 1 hour after the infusion is complete. The infusion should be discontinued if a reaction occurs, and treatment of the reaction should be instituted. Following infusion, flush line with NS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200012\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Inducing and maintaining clinical response and remission in adults with moderately to severely active Crohn disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn disease therapies and inhibitors of tumor necrosis factor-alpha (TNF-alpha).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis:</b> As monotherapy for the treatment of patients with relapsing forms of multiple sclerosis (MS). Natalizumab increases the risk of PML. When initiating and continuing treatment with natalizumab, consider whether the expected benefit of natalizumab is sufficient to offset this risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canada labeling:</i> Treatment of relapsing forms of multiple sclerosis in patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200003\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (32% to 38%), fatigue (10% to 27%), depression (&le;19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;17%), gastroenteritis (&le;11%), abdominal distress (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (8% to 19%), limb pain (16%), back pain (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&le;22%), lower respiratory tract infection (&le;17%), flu-like symptoms (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (11% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (5% to 6%), chest discomfort (&le;5%), syncope (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Vertigo (&le;6%), dysesthesia (3%), rigors (&le;3%), drowsiness (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (&le;7%), pruritus (&le;4%), urticaria (&le;2%), thermal injury (1%), night sweats (&le;1%), xeroderma (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (&le;5%), amenorrhea (&le;2%), ovarian cyst (&le;2%), weight changes (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (10%), tooth infection (&le;9%), dyspepsia (&le;5%), abdominal pain (&le;4%), constipation (&le;4%), toothache (&le;4%), flatulence (&le;3%), aphthous stomatitis (&le;2%), cholelithiasis (&le;1%), gingival disease (infection: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal infection (&le;10%), vaginitis (&le;10%), urinary frequency (&le;9%), dysmenorrhea (2% to 6%), urinary incontinence (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (acute: 2% to 4%; serious acute: &le;1%; delayed: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (9% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes virus infection (&le;8%), viral infection (&le;7%), serious infection (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps (&le;5%), tremor (1% to 3%), joint swelling (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (&le;8%), cough (&le;7%), tonsillitis (&le;7%), pharyngolaryngeal pain (&le;6%), epistaxis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Limb injury (3%), laceration (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acne vulgaris, agitation, anaphylactoid reaction, anaphylaxis, anemia, angina pectoris, appendicitis, aspergillosis (bronchopulmonary), decreased hemoglobin (mild, transient), dizziness, dyspnea, erythema, exacerbation of Crohn&rsquo;s disease, fever, flushing, gastroenteritis (cryptosporidial), hemolytic anemia, hepatic failure, hepatitis (cytomegalovirus), hepatotoxicity, herpes simplex encephalitis, hypotension, immune reconstitution syndrome, increased serum bilirubin, infection (<i>Burkholderia cepacia</i>), JC virus infection, joint stiffness, lethargy, leukocytosis, meningitis (herpes), nasopharyngitis, opportunistic infection (including bronchopulmonary infections, meningitis, and progressive multifocal leukoencephalopathy [PML]), muscle spasm, myasthenia, nail disease (onychorrhexis), paresis, pericarditis (case report), petechiae, pharyngitis, pneumonia (includes pneumonia caused by <i>Pneumocystis jirovecii</i> and varicella), psychomotor disturbance (hyperactivity), pulmonary infection (<i>Mycobacterium avium intracellulare</i>), suicidal ideation, tachycardia, thrombocytopenia, thrombophlebitis, vasodilatation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200016\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to natalizumab or any component of the formulation; current or history of progressive multifocal leukoencephalopathy (PML)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canada labeling:</i> Additional contraindications (not in US labeling): Immunocompromised patients as a result of immunosuppressant or antineoplastic therapy, or immunodeficiencies (eg, HIV, leukemia, lymphoma)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200001\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity, including acute liver failure requiring transplant, has been reported with use. Signs of hepatotoxicity, including transaminase and bilirubin elevation occurred as early as 6 days after the first dose; may recur with treatment rechallenge; discontinue use with jaundice or signs/symptoms of hepatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpes infection: Serious, life-threatening herpes infections, including fatalities (herpes encephalitis or herpes meningitis infections caused by herpes simplex and varicella zoster viruses) have occurred within a few months to several years of natalizumab treatment. Monitor patients for signs/symptoms of meningitis and encephalitis. In the presence of herpes encephalitis or meningitis, discontinue therapy. Acute retinal necrosis (ARN), a fulminant viral infection of the retina caused by the family of herpes viruses (eg, varicella zoster, herpes simplex virus) has also been observed during natalizumab treatment. Some cases occurred in patients with CNS herpes infections (eg, herpes meningitis, encephalitis); serious cases may result in blindness. Following diagnosis of ARN, consider discontinuation of natalizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/antibody formation: Hypersensitivity reactions including serious systemic reactions (eg, anaphylaxis) have occurred in &lt;1% of patients. Symptoms may include dizziness, fever, flushing, rigors, hypotension, dyspnea, nausea, pruritus, rash, and urticaria and typically occur within 2 hours of starting the infusion. Reactions are generally associated with antibodies to natalizumab; consider the possibility of antibodies in patients who have hypersensitivity reactions. Patients with an extended interruption in therapy following a short exposure (1 to 2 infusions) to natalizumab may be at an increased risk for developing anti-natalizumab antibodies and/or hypersensitivity reactions following reinitiation of therapy. If a hypersensitivity reaction occurs, discontinue use; patients who have developed hypersensitivity reactions should not be re-treated. Antibody formation (which occurs in about 10% of patients) is associated with a decrease in natalizumab levels and a decrease in the efficacy of natalizumab. Antibody testing should be performed in any patient when there is a suspicion of persistent antibodies and should be considered in patients that resume therapy following a period of dosage interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution inflammatory syndrome (IRIS): IRIS has been reported in patients after discontinuing natalizumab due to PML. In most cases, this occurred within days to weeks after plasma exchange was used in an attempt to remove natalizumab. IRIS is a rare condition which is characterized by severe inflammation during or following immune system recovery, which can result in a decline in patient condition, including neurological symptoms and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Use may be associated with an increased risk of infections, including opportunistic infections and serious herpes infections (rare, postmarketing reports; concurrent use of antineoplastic, immunosuppressant [including short-course corticosteroids], or immunomodulating agents may increase this risk); discontinue therapy until successful resolution of the infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lab test abnormalities: Reversible increases in circulating lymphocytes, monocytes, eosinophils, basophils, and nucleated red blood cells may occur; changes persist during natalizumab exposure but usually return to baseline within 16 weeks after the last dose. Mild transient decreases in hemoglobin levels may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: <b>[US Boxed Warning]: Natalizumab increases the risk of developing fatal or disabling progressive multifocal leukoencephalopathy (PML, an opportunistic viral infection of the brain caused by the JC virus). Risk factors for development of PML include duration of therapy (especially &gt;2 years), prior use of immunosuppressants (eg, azathioprine, cyclophosphamide, methotrexate, mitoxantrone, mycophenolate), and the presence of anti JC virus antibodies. Monitor for any new signs/symptoms suggestive of PML; immediately withhold treatment at the first sign or symptom suggesting PML. For diagnosis of PML, an evaluation should include a gadolinium-enhanced MRI scan of the brain and (if indicated) analysis of CSF for JCV DNA.</b> Cases of PML have been diagnosed based on MRI findings and the detection of JCV DNA in the CSF without specific PML signs/symptoms (including progressive weakness on one side of the body, limb clumsiness, visual disturbance, changes in thinking, memory, personality or orientation) reported. Use should ordinarily be avoided in patients who are significantly immunocompromised or receiving chronic immunosuppressant or immunomodulatory therapy. For an early diagnosis of PML, consider periodic monitoring for radiographic signs of PML. Anti-JCV antibody testing prior to or during treatment may be considered; testing should not be used to diagnose PML and should not be performed for at least 2 weeks after plasma exchange. Patients who are anti-JCV antibody negative are still at risk for developing PML, although the risk is lower; therefore, patients with a negative anti-JCV antibody test result should be retested periodically. A brain MRI scan (baseline) should be obtained prior to initiating therapy in MS patients and should be considered in patients with Crohn disease. PML has also been reported following discontinuation in patients who did not have findings suggestive of PML at the time of discontinuation; patients should be monitored for signs and symptoms of PML for at least 6 months after discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Crohn disease: Natalizumab should not be used in combination with immunosuppressants or tumor necrosis factor (TNF) inhibitors in patients with Crohn disease; aminosalicylates may be used concurrently with natalizumab. For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: There are no data available concerning the effect of vaccination or secondary transmission of infection by live vaccines in patients receiving natalizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use should be restricted to patients with inadequate response to or intolerant of other therapies for Crohn disease or multiple sclerosis. Carefully evaluate the overall benefit to risk in patients that develop persistent antibodies to natalizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: <b>[US Boxed Warning]: Access is restricted through a REMS program called the TOUCH Prescribing Program;</b> prescribers and pharmacies must be certified with the Tysabri Outreach Unified Commitment to Health (TOUCH) Prescribing Program. Patients must also be enrolled in the TOUCH Prescribing Program (800-456-2255) to receive natalizumab (MS-TOUCH for multiple sclerosis or CD-TOUCH for Crohn disease).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299746\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200005\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10252&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: May enhance the adverse/toxic effect of Natalizumab.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200018\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Natalizumab crosses the placenta (Haghikia 2015). Hematological alterations such as anemia and thrombocytopenia have been noted following maternal use during pregnancy. The risk of spontaneous abortion may also be increased (Amato 2015; Ebrahimi 2015; Haghikia 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to natalizumab should be enrolled in the Tysabri Pregnancy Exposure Registry 1-800-456-2255.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200019\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Natalizumab is present in human milk; however, the effects on infants are unknown. Although natalizumab is not orally bioavailable, most sources recommend the avoidance of breastfeeding (Amato 2015; Ghezzi 2013). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200009\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Symptoms of hepatotoxicity (eg, elevated serum transaminases, bilirubin); hypersensitivity reactions during, and for 1 hour after, infusion; symptoms of persistent antibody-positivity (eg, anxiety, dizziness, dyspnea, feeling cold, flushing, headache, hypertension, myalgia, nausea, pruritus, pyrexia, rigors, tachycardia, tremor, urticaria or, vomiting); signs/symptoms of meningitis and encephalitis; signs/symptoms of acute retinal necrosis.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiographic signs of PML periodically; antibody testing is recommended if persistent antibodies are suspected and repeated in 3 months in all patients with documented positivity on initial test; consider antibody testing in patients that resume therapy following a period of dosage interruption.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Baseline brain MRI scan; if PML is suspected, obtain gadolinium-enhanced brain MRI scan and CSF analysis for JC viral DNA. Evaluate for signs or symptoms of progressive multifocal leukoencephalopathy during treatment and for 6 months after discontinuation. <b>Note:</b> Transient and reversible leukocytosis (excluding neutrophils) and mildly reduced hemoglobin may occur with treatment and may require ~4 months for return to baseline values after the last dose; anti-JCV antibody (prior to therapy and periodically during therapy).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200000\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Natalizumab is a monoclonal antibody against the alpha-4 subunit of integrin molecules. These molecules are important to adhesion and migration of cells from the vasculature into inflamed tissue. Natalizumab blocks integrin association with vascular receptors, limiting adhesion and transmigration of leukocytes. Efficacy in specific disorders may be related to reduction in specific inflammatory cell populations in target tissues. In multiple sclerosis, efficacy may be related to blockade of T-lymphocyte migration into the central nervous system; treatment results in a decreased frequency of relapse. In Crohn disease, natalizumab decreases inflammation by binding to alpha-4 integrin, blocking adhesion and migration of leukocytes in the gut. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200015\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Crohn disease: 2.4 to 8 L; Multiple sclerosis: 3.8 to 7.6 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Crohn disease: 3 to 17 days; Multiple sclerosis: 7 to 15 days </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323460\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Tysabri Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/15 mL (15 mL): $7,416.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539898\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tizabri (UA);</li>\n      <li>Tysabri (AE, AT, AU, BB, BE, BG, BH, BR, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i>. 2015;29(3):207-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/25773609 /pubmed\" target=\"_blank\" id=\"25773609 \">25773609 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloomgren G, Richman S, Hotermans C, et al, &ldquo;Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy,&rdquo; <i>N Engl J Med</i>, 2012, 366(20):1870-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/22591293/pubmed\" target=\"_blank\" id=\"22591293\">22591293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. <i>Mult Scler</i>. 2015;21(2):198-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/v/pubmed\" target=\"_blank\" id=\"v\">v</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Rev Clin Immunol</i>. 2013;9(7):683-691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/23899239 /pubmed\" target=\"_blank\" id=\"23899239 \">23899239 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghosh S, Goldin E, Gordon FH, et al, &ldquo;Natalizumab for Active Crohn's Disease,&rdquo; <i>N Engl J Med</i>, 2003, 348(1):24-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/12510039/pubmed\" target=\"_blank\" id=\"12510039\">12510039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. <i>JAMA Neurol</i>. 2014; 71(7):891-895.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/24821217 /pubmed\" target=\"_blank\" id=\"24821217 \">24821217 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koralnik IJ, &ldquo;New Insights Into Progressive Multifocal Leukoencephalopathy,&rdquo; <i>Curr Opin Neurol</i>, 2004, 17(3):365-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/15167073/pubmed\" target=\"_blank\" id=\"15167073\">15167073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polman CH, O&rsquo;Connor PW, Havrdova E, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis,&rdquo; <i>N Engl J Med</i>, 2006, 354:899-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/16510744/pubmed\" target=\"_blank\" id=\"16510744\">16510744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudick RA, Stuart WH, Calabresi PA et al, &ldquo;Natalizumab Plus Interferon Beta-1a for Relapsing Multiple Sclerosis,&rdquo; <i>N Engl J Med</i>, 2006, 354:911-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/16510745/pubmed\" target=\"_blank\" id=\"16510745\">16510745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, Colombel JF, Enns R, et al, &ldquo;Natalizumab Induction and Maintenance Therapy for Crohn's Disease,&rdquo; <i>N Engl J Med</i>, 2005, 353(18):1912-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/16267322/pubmed\" target=\"_blank\" id=\"16267322\">16267322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Targan SR, Feagan BG, Fedorak RN, et al, &ldquo;Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial,&rdquo; <i>Gastroenterology</i>, 2007, 132(5):1672-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/17484865/pubmed\" target=\"_blank\" id=\"17484865\">17484865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tysabri (natalizumab) [prescribing information]. Cambridge, MA: Biogen Idec Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tysabri (natalizumab) [product monograph]. Mississauga, Ontario, Canada: Biogen Idec Canada Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Assche G, Van Ranst M, Sciot R, et al, &ldquo;Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease,&rdquo; <i>N Engl J Med</i>, 2005, 353(4):362-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/natalizumab-drug-information/abstract-text/15947080/pubmed\" target=\"_blank\" id=\"15947080\">15947080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yousry TA, Major EO, Ryschkewitsch C et al, &ldquo;Evaluation of Patients Treated With Natalizumab for Progressive Multifocal Leukoencephalopathy,&rdquo; <i>N Engl J Med</i> 2006, 354:924-33.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10252 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709166\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F200027\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5594359\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F200046\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F200029\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F200030\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F200031\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F200032\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200011\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F199999\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234120\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7885623\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F200013\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F200012\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F200003\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200016\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200001\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299746\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F200005\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F200018\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F200019\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F200009\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200000\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F200015\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323460\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539898\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10252|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=natalizumab-patient-drug-information\" class=\"drug drug_patient\">Natalizumab: Patient drug information</a></li></ul></div></div>","javascript":null}